Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-03-05

Clinical Trial Update: GLORIA-AF Registry Program (Phase I)

View source ↗

Summary

The GLORIA-AF Registry Program Phase I update from Boehringer Ingelheim in atrial fibrillation has completed, with results posted in March 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Atrial Fibrillation | Status: COMPLETED | Results posted: 2014-03-05